Selected C8 two-chain linkers yield enhanced adenosine receptor affinity. A1 receptor antagonists are considered agents for Parkinson's disease therapy. A2A receptor antagonists are considered agents for Parkinson's disease therapy. Introduction of a para-chloro substitution govern A2A receptor selectivity.